Revenue Recognition (Tables)

6 Months Ended

Jun. 30, 2019

Revenue Recognition

Disaggregation Of Revenue

In thousands of US dollars ($)		Three Months Ended June 30, 2019						Six Months Ended June 30, 2019
Products By Geographic Area	Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues
Product Sales – Point-in-time	$	15	$	15	$	—	$	15	$	15	$	—
License Fee – Over time		68		—		68		136		—		136
Total Drug Products		83		15		68		151		15		136
Concentrate Products
Product Sales – Point-in-time		14,268		12,822		1,446		29,264		25,746		3,518
License Fee – Over time		495		495		—		990		990		—
Total Concentrate Products		14,763		13,317		1,446		30,254		26,736		3,518
Net Revenue	$	14,846	$	13,332	$	1,514	$	30,405	$	26,751	$	3,654
		Three Months Ended June 30, 2018						Six Months Ended June 30, 2018
Products By Geographic Area		Total		U.S.		Rest of World		Total		U.S.		Rest of World
Drug Revenues
License Fee – Over time	$	68		—	$	68	$	136		—	$	136
Concentrate Products
Product Sales – Point-in-time		14,340		12,856		1,484		28,717		25,329		3,388
License Fee – Over time		505		505		—		1,009		1,009		—
Total Concentrate Products		14,845		13,361		1,484		29,726		26,338		3,388
Net Revenue	$	14,913	$	13,361	$	1,552	$	29,862	$	26,338	$	3,524

Contract Balances

In thousands of US dollars ($)	June 30, 2019		December 31, 2018
Receivables, which are included in "Trade and other receivables"	$	5,389	$	6,980
Contract liabilities	$	13,203	$	14,329